NewsNovo
The $12 million upfront payment RedHill Biopharma Ltd.
(NASDAQ: RDHL) made to acquire exclusive commercialization rights to Rebyota and Clenpiq from Ferring Pharmaceuticals looks lean against the products' combined approximately $37.5 million in U.S.
The risk is that what RedHill actually retains, after royalties of 5% to 20% of net sales, undisclosed inventory commitments, and contingent payments, has not been made visible.
The case for the deal turns on what the existing accounts already show.
Keep reading